The discovery of the significance of RNA activity in cell protein production is one of the most important medical breakthroughs in recent years. Silence Therapeutics has developed its own RNA technology, along with proprietary delivery systems. Combined, these enable the development of therapeutics for diseases with high unmet medical need.
Silence is one of very few listed companies with the ability to modulate gene expression both up and down, in vivo.
The RNA technology field has high barriers to entry, with much investment and know-how required to develop RNA drugs to this stage. Our technology is already in the clinic and has been used in Phase 2 trials. We also have a robust IP estate defending our proprietary technology.
Our proprietary gene silencing module can be designed to regulate expression of potentially any gene, and our delivery systems need no immune suppressants. Effective delivery capability will be key for the next stage in genetic medicine, targeting disease right at the cause.
Silence has an expanding early stage pipeline and an embedded algorithm for cost effective pre-clinical drug development with clear go/no-go milestones. We take pride in our research collaborations with world leading research institutions such as Oxford University, Cambridge University and Imperial College London, to develop the most promising drug candidates.
Free float, as defined by the AIM Rules, is 56.06% of the current issued share capital.
|Shareholder||Number of shares||Percentage of share capital|
|Henderson Global Investors||5,072,593||7.27%|
|Woodford Investment Management LLP||4,166,666||5.97%|
*total holding 12,085,371 including indirect holdings
Last updated: September 2016
Number of securities in issue: 69,801,624 ordinary shares
Changes in share price:
|Last 30 days||Last 4 years|
Results, Reports & Presentations
Full Year & Half Year results releases
Half Year Results 2016
Full Year Results 2015
Half Year Results 2015
Full Year Results 2014
Half Year Results 2014
Full Year Results 2013
Half Year Results 2013
Full Year Results 2012
Half Year Results 2012
Full Year Results 2011
Half Year Results 2011
Full Year Results 2010
Atu027 Phase 2a Pancreatic Cancer Interim Analysis
February 2015 Investor Presentation
January 2015 Proactive Investors Presentation
December 2014 Capital Markets Presentation
May 2014 Investor Presentation
May 2014 Science Appendix
March 2013 Fundraising Presentation
March 2013 Science Appendix
Silence Therapeutics has not adopted a code on corporate governance but takes corporate governance very seriously and is currently working towards compliance with a formal UK code. The Company’s existing corporate governance arrangements are set out below.
Policy and strategy
The Board of Directors is responsible for approving the Company’s policy and strategy. It meets on a regular basis and has a schedule of matters specifically reserved for it to consider. The executive management team supply the Board with appropriate and timely information and the Directors are free to seek any further information they consider necessary. All Directors have access to regular training and independent professional advice at the Company’s expense.
The Board is responsible for maintaining a strong system of internal controls to safeguard shareholders’ investment and the Company’s assets and for reviewing its effectiveness. The system of internal financial control is designed to provide reasonable, but not absolute, assurance against material misstatement or loss.
An audit committee has been established and comprises three non-executive directors. The Committee is responsible for ensuring that the financial performance of the Group is properly monitored and reported on, as well as meeting the Company’s auditor and reviewing any reports from the auditor regarding accounts and internal control systems.
The Remuneration Committee assists the board in the discharging of its responsibilities related to remuneration of the Company’s executive officers
Chairman: Andy Richards
Members: Stephen Parker, Alistair Gray
The Audit Committee assists the board’s oversight of accounting and financial reporting processes and the audits of the Company’s financial statements
Chairman: Alistair Gray
Members: Stephen Parker, Andy Richards
The Nominations Committee recommends to the board those persons to be nominated for election as directors at any shareholders meeting
Chairman: Stephen Parker
Members: Alistair Gray, Andy Richards
Relations with shareholders
Silence Therapeutics values the views of its shareholders and recognises their interest in the Company’s strategy and performance. The Annual General Meeting is used to communicate with private investors and they are encouraged to participate.